Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study-Reference-Cited by-同舟云学术

Childhood high-risk acute lymphoblastic leukemia in first remission: results after chemotherapy or transplant from the AIEOP ALL 2000 study

Published:2014-03-06 Issue:10 Volume:123 Page:1470-1478
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Conter Valentino¹,Valsecchi Maria Grazia²,Parasole Rosanna³,Putti Maria Caterina⁴,Locatelli Franco⁵⁶,Barisone Elena⁷,Lo Nigro Luca⁸,Santoro Nicola⁹,Aricò Maurizio¹⁰,Ziino Ottavio¹¹,Pession Andrea¹²,Testi Anna Maria¹³,Micalizzi Concetta¹⁴,Casale Fiorina¹⁵,Zecca Marco¹⁶,Casazza Gabriella¹⁷,Tamaro Paolo¹⁸,La Barba Gaetano¹⁹,Notarangelo Lucia Dora²⁰,Silvestri Daniela¹²,Colombini Antonella¹,Rizzari Carmelo¹,Biondi Andrea¹,Masera Giuseppe¹,Basso Giuseppe⁴

Affiliation:

1. Department of Pediatrics, Ospedale S. Gerardo, University of Milano-Bicocca, Fondazione MBBM, Monza, Italy;

2. Center of Biostatistics for Clinical Epidemiology, Department of Health Sciences, University of Milano-Bicocca, Milan, Italy;

3. Department of Pediatric Hemato-Oncology, Ospedale Pausilipon, Napoli, Italy;

4. Department of Woman and Child Health, Hemato-Oncology Division, University of Padova, Azienda Ospedale Padova, Padova, Italy;

5. Department of Pediatric Hemato-Oncology, IRCCS Ospedale Bambino Gesù, Roma, Italy;

6. University of Pavia, Pavia, Italy;

7. Department of Pediatric Hemato-Oncology, Regina Margherita Children’s Hospital, Torino, Italy;

8. Department of Pediatric Hemato-Oncology, Azienda Policlinico - OVE, Catania, Italy;

9. Department of Pediatric Hemato-Oncology, University of Bari, Bari, Italy;

10. Istituto Toscano Tumori, Firenze, Italy;

11. Department of Pediatric Hemato-Oncology, University of Palermo, Palermo, Italy;

12. Department of Pediatric Hemato-Oncology, University of Bologna, Bologna, Italy;

13. Department of Cellular Biotechnologies and Hematology, University La Sapienza, Roma, Italy;

14. Department of Pediatric Hemato-Oncology, IRCCS I.G. Gaslini, Genova, Italy;

15. Department of Pediatric Hemato-Oncology, University of Napoli, Napoli, Italy;

16. Department of Pediatric Hemato-Oncology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy;

17. Department of Pediatric Hemato-Oncology, University of Pisa, Pisa, Italy;

18. Department of Pediatric Hemato-Oncology, Institute for Maternal and Child Health, IRCCS Burlo Garofalo, Trieste, Italy;

19. Department of Pediatric Hemato-Oncology, Ospedale Civile, Pescara, Italy; and

20. Department of Pediatric Hemato-Oncology and Bone Marrow Transplant Unit, Spedali Civili, Brescia, Italy

Abstract

Key Points Intensive BFM therapy is effective for HR childhood ALL if low MRD levels are achieved at the end of the induction/consolidation phase. Childhood ALL with high MRD levels at the end of induction/consolidation phase has a poor prognosis despite intensive BFM therapy or HSCT.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/123/10/1470/1374084/1470.pdf

Reference26 articles.

1. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.;Flohr;Leukemia,2008

2. Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.;Conter;Blood,2010

3. Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.;Schrappe;Blood,2011

4. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.;van Dongen;Lancet,1998

5. Intensive BFM chemotherapy for childhood ALL: interim analysis of the AIEOP-ALL 91 study. Associazione Italiana Ematologia Oncologia Pediatrica.;Conter;Haematologica,1998

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of blinatumomab in children with de novo Ph-negative B-lineage acute lymphoblastic leukemia and slow clearance of minimal residual disease;Pediatric Hematology/Oncology and Immunopathology;2024-04-16

2. Four Additional Doses of PEG-L-Asparaginase During the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study;Journal of Clinical Oncology;2023-12-14

3. Reduced‐intensity therapy for relapsed Philadelphia chromosome‐positive leukemia;Pediatric Blood & Cancer;2023-12-05

4. The current landscape: Allogeneic hematopoietic stem cell transplant for acute lymphoblastic leukemia;Best Practice & Research Clinical Haematology;2023-09

5. Improved Outcome for ALL by Prolonging Therapy for IKZF1 Deletion and Decreasing Therapy for Other Risk Groups;Journal of Clinical Oncology;2023-09-01